Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)

BACKGROUND: We previously reported the good feasibility and favorable efficacy of perioperative capecitabine plus oxaliplatin (CapeOx) in patients (pts) with clinical T3(SS)/T4a(SE) N1-3 M0 gastric cancer (GC) in a phase II study in which the pathological response rate, the primary endpoint, of 54.1...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuyama, Jin, Terazawa, Tetsuji, Goto, Masahiro, Kawabata, Ryohei, Endo, Shunji, Imano, Motohiro, Fujita, Shoichiro, Akamaru, Yusuke, Taniguchi, Hirokazu, Tatsumi, Mitsutoshi, Lee, Sang-Woong, Kawakami, Hisato, Kurokawa, Yukinori, Shimokawa, Toshio, Sakai, Daisuke, Kato, Takeshi, Fujitani, Kazumasa, Satoh, Taroh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982391/
https://www.ncbi.nlm.nih.gov/pubmed/35380725
http://dx.doi.org/10.1093/oncolo/oyab061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982391/
https://www.ncbi.nlm.nih.gov/pubmed/35380725
http://dx.doi.org/10.1093/oncolo/oyab061

Ejemplares similares